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Summary
Sequential, multiple assignment, randomized trial (SMART) designs have become increasingly popular in
the field of precision medicine by providing a means for comparing sequences of treatments tailored to
the individual patient, i.e., dynamic treatment regime (DTR). The construction of evidence-based DTRs
promises a replacement to adhoc one-size-fits-all decisions pervasive in patient care. However, there are
substantial statistical challenges in sizing SMART designs due to the complex correlation structure between
the DTRs embedded in the design. Since the primary goal of SMARTs is the construction of an optimal
DTR, investigators are interested in sizing SMARTs based on the ability to screen out DTRs inferior to
the optimal DTR by a given amount which cannot be done using existing methods. In this paper, we fill
this gap by developing a rigorous power analysis framework that leverages multiple comparisons with the
best methodology. Our method employs Monte Carlo simulation in order to compute the minimum number
of individuals to enroll in an arbitrary SMART. We will evaluate our method through extensive simulation
studies. We will illustrate our method by retrospectively computing the power in the Extending Treatment
Effectiveness of Naltrexone SMART study.
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1. Introduction
Sequential, multiple assignment, randomized trial (SMART) designs have gained considerable attention in
the field of precision medicine by providing an empirically rigorous experimental approach for comparing
sequences of treatments tailored to the individual patient, i.e., dynamic treatment regime (DTR) (Lavori and
others, 2000; Murphy, 2005; Lei and others, 2012). A DTR is a treatment algorithm implemented through a
sequence of decision rules which dynamically adjusts treatments and dosages to a patient’s unique changing
need and circumstances (Murphy and others, 2001; Murphy, 2003; Robins, 2004; Nahum-Shani and others,
2012; Chakraborty and Moodie, 2013; Chakraborty and Murphy, 2014; Laber and others, 2014). SMART
studies are motivated by scientific questions concerning the construction of an effective DTR. The sequential
randomization in a SMART gives rise to several DTRs which are embedded in the SMART by design. Many
SMARTs are designed to compare these embedded DTRs and identify those showing greatest potential for
improving a primary clinical outcome. The construction of evidence-based DTRs promises an alternative to
adhoc one-size-fits-all decisions pervasive in patient care.
The advent of SMART designs poses interesting statistical challenges in the planning phase of the trials.
In particular, performing power analyses to determine an appropriate sample size of individuals to enroll
becomes mathematically difficult due to the complex correlation structure between the DTRs embedded in
the design. Previous work in planning the sample size for SMARTs includes sizing pilot SMARTs (small scale
versions of a SMART) so that each sequence of treatments has a pre-specified number of individuals with
some probability by the end of the trial (Almirall and others, 2012; Hwanwoo and others, 2016). The central
questions motivating this work are feasibility of the investigators to carry out the trial and acceptability of
the treatments by patients. These methods do not provide a means to size SMARTs for comparing DTRs in
terms of a primary clinical outcome.
Alternatively, Crivello and others (2007(a)) proposed a new objective for SMART sample size planning.
The question they address is how many individuals need to be enrolled so that the best DTR has the
largest sample estimate with a given probability (Crivello and others, 2007(b)). Such an approach based on
estimation alone fails to account for the uncertainty in the mean DTR sample estimates. In particular, some
DTRs may be statistically indistinguishable from the true best for the given data in which case they should
not necessarily be excluded as suboptimal. Furthermore, the true best DTR may only be superior in efficacy
to other DTRs by an amount which is clinically insignificant at the cost of providing treatments that are more
burdensome and costly compared to other DTRs. Crivello and others (2007) also discussed sizing SMARTs to
attain a specified power for testing hypotheses which compare only two treatments or two embedded DTRs
as opposed to comparing all embedded DTRs. The work of Crivello and others (2007) focused mainly on a
particular common two-stage SMART design whereas our method is applicable to arbitrary SMART designs.
One of the main goals motivating SMARTs is to identify the optimal DTRs. It follows that investigators
are interested in sizing SMARTs based on the ability to exclude DTRs which are inferior to the optimal DTR
by a clinically meaningful amount. This cannot be done with existing methods. In this paper, we fill the
current methodological gap by developing a rigorous power analysis framework that leverages the multiple
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comparisons with the best (MCB) methodology in order to construct a set of optimal DTR which excludes
DTRs inferior to the best by a specified amount (Hsu, 1981; Hsu, 1984; Hsu, 1996). Our method is applicable
to an arbitrary SMART design. There are two main justifications for using multiple comparisons with the
best. 1) MCB involves fewer comparisons compared to methods which involve all pairwise comparisons, and
thus, it yields greater power for the same number of enrolled individuals with all else being equal (Ertefaie
and others, 2015); 2) MCB permits construction of a set of more than one optimal DTR from which the
physician and patient may choose.
In Section 2, we give a brief overview of SMARTs and relevant background on estimation and MCB. In
Section 3, we present our power analysis framework. In Section 4, we look at properties of our method. In
Sections 5 and 6, we demonstrate the validity of our method through extensive simulation studies. In Section
7, we will apply our method to retrospectively compute the power in the Extending Treatment Effectiveness
of Naltrexone SMART study. In the accompanying appendix, we provide additional details about estimation
and our simulation study. In the future, an R package called ”smartsizer” will be made freely available to
assist investigators with sizing SMARTs.
2. PRELIMINARIES
2.1 Sequential Multiple Assignment Randomized Trials
In SMART design, individuals proceed through multiple stages of randomization such that some or all
individuals may be randomized more than once. Additionally, treatment assignment is often tailored to
the individual’s ongoing response status (Nahum-Shani and others, 2012). For example, in the Extending
Treatment Effectiveness of Naltrexone (EXTEND) SMART study (see Figure 1 for the study design and
Nahum-Shani and others, 2017 for more details about this study), individuals were initially randomized to
two different criteria of non-response: lenient or stringent. Specifically, all individuals received the same fixed
dosage of naltrexone (NTX) – a medication that blocks some of the pleasurable effects resulting from alcohol
consumption. After the first two weeks, individuals were evaluated weekly to assess response status.
Individuals assigned to the lenient criterion were classified as non-responders as soon as they had five or
more heavy drinking days during the first eight weeks of the study, whereas those assigned to the stringent
criterion were classified as non-responders as soon as they had two or more heavy drinking days during the
first eight weeks. As soon as participants were classified as non-responders, they transitioned to the second
stage where they were randomized to two subsequent rescue tactics: either switch to combined behavioral
intervention (CBI) or add CBI to NTX (NTX + CBI). At week 8, individuals who did not meet their assigned
non-response criterion were classified as responders and re-randomized to two subsequent maintenance inter-
ventions: either add telephone disease management (TDM) to the NTX (NTX + TDM) or continue NTX
alone. Note that the second stage treatment options in the SMART are tailored to the individual’s response
status. That is, individuals are randomized to different subsequent interventions depending on their early
response status. This leads to a total of eight DTRs that are embedded in this SMART by design. For ex-
ample, one of these DTRs recommends to start the treatment with NTX and monitor drinking behaviors
weekly using the lenient criterion (i.e., 5 or more heavy drinking days) to classify the individual as a non-
responder. As soon as the individual is classified as a non-responder, add CBI (NTX + CBI); if at week
eight the individual is classified as a responder, add TDM (NTX + TDM). Many SMARTs are motivated
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by scientific questions pertaining to the comparison of the multiple DTRs that are embedded in the SMART
by design. For example, determining an optimal EDTR in the EXTEND may guide in evaluating a patient’s
initial response to NTX and in selecting the best subsequent treatment.
In the next section, we discuss how the multiple comparison with the best (MCB) procedure (Hsu (1981),
Hsu (1984), Hsu (1996)) can be used to address scientific questions concerning the optimal EDTR.
2.2 Determining a Set of Best DTRs using Multiple Comparison with the Best
The MCB procedure can be used to identify a set of optimal EDTRs which cannot be statistically distin-
guished from the true best EDTR.
In order to carry out MCB, we must be able to estimate the mean outcome of each EDTR. Let the
true mean outcome vector of EDTRs be denoted by θ = (θ1, ..., θN )
t where N is the total number of DTRs
embedded in the SMART design. Assume θˆ is a consistent estimator for θ such that
√
n(θˆ − θ) d→ N(0,Σ), (2.1)
where Σ is the asymptotic covariance matrix and n is the total number of individuals enrolled in the SMART.
Proposition 1 in Appendix A of the supplementary material presents two estimators for θ which satisfy (2.1).
The MCB procedure entails comparing the mean outcome of each EDTR to the mean outcome of the
best EDTR standardized by the standard deviation of their difference. In particular, EDTRi is considered
statistically indistinguishable from the true best EDTR for the available data if and only if the standardized
difference
θˆi − θˆj
σij
> −ci,α for all j 6= i where σij =
√
Var(θˆi − θˆj) and ci,α > 0 is chosen such that the set of
best EDTRs includes the true best EDTR with at least a specified probability 1 − α. Then, the set of best
can be written as Bˆ := {EDTRi : θˆi > max
j 6=i
[θˆj − ci,ασij ]} where ci,α depends on α and the covariance matrix
Σ. The above α represents the type I error rate for excluding the best EDTR from Bˆ. To control the type I
error rate, it suffices to consider the situation in which the true mean outcomes are all equal.
Then, a sufficient condition for the type I error rate to be at most α is to choose ci,α so that the set of
best DTRs includes each EDTR with probability at least 1− α:
P(EDTRi ∈ Bˆ | θ1 = · · · = θN ) = 1− α for all i = 1, ..., N . (2.2)
It can be shown it is sufficient for ci,α to satisfy:∫
P (Zj 6 z + ci,ασij , for all j = 1, ..., N) dφ(z) = 1− α, (2.3)
where φ(z) is the marginal cdf of Zi and (Z1, ..., ZN )
t ∼ N (0,Σ). Observe that ci,α > 0 is a function of Σ
and α 6 0.5, but not of the number of individuals n. The integral in (2.3) is analytically intractable, but the
ci,α may be determined using Monte Carlo methods.
The MCB procedure has both applied and theoretical advantages which justify its use to compare DTRs
that are embedded in a SMART. In particular, in the event that more than one EDTR is included in the
set of best, MCB provides provides clinicians with a set of optimal treatment protocols to choose from in
order to individualize a patient’s treatment. Identifying a set of DTRs is useful in the situation where the
treatment suggested by one DTR may not be feasible for the patient due to lack of insurance coverage, drug
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interactions, and/or allergies. In addition to the practical advantages, MCB provides a set with fewer DTRs
compared to other methods since fewer comparisons yields increased power to exclude inferior DTRs from the
set of best. Another statistical advantage of MCB is that it incorporates the uncertainty in sample estimates
by providing a set of optimal DTRs instead of simply choosing the largest sample estimate.
Although MCB has theoretical and applied merits over alternative approaches, it comes with the price of
additional statistical challenges such as that imposed by the correlation structure between EDTRs expressed
through Σ and the numerical inconvenience of the max operator. The correlation structure between EDTR
outcomes arises, in part, due to overlapping interventions in distinct DTRs and because patients’ treatment
histories may be consistent with more than a single DTR. For example, patients in distinct EDTRs of the
EXTEND trial all receive naltrexone. Also, patients who are are classified as responders in stage 2 and
subsequently randomized to NTX will be consistent with two EDTRs: one where non-responders are offered
CBI and one where non-responders are offered NTX + CBI. Hence, deriving a convenient univariate test
statistic unfeasible and many computations analytically intractable. In order to overcome these challenges,
we will derive a form of the power function for which Monte Carlo simulation can be applied in the following
section.
3. Methods
Let ∆min > 0 be the minimum detectable difference, α be the type I error rate, and Σ be the asymptotic
covariance matrix of
√
nθˆ where n is the total number of individuals enrolled in the SMART. Furthermore,
let 1− β denote the desired minimum power to exclude EDTRs with true outcome ∆min or more away from
that of the true best outcome. Let ∆ be the vector of effect sizes. So, ∆i = θN − θi.
We wish to exclude all i from the set of best for which ∆i > ∆min. We have that
Power = Pθ,Σ,n
 ⋂
i:∆i>∆min
{
θˆi < max
j 6=i
[θˆj − ci,ασij ]
} . (3.4)
However, the max operator makes (3.4) analytically and computationally complicated, so we will instead
bound the RHS of the following inequality:
PΣ,n
 ⋂
i:∆i>∆min
{
θˆi < max
j 6=i
[θˆj − ci,ασij ]
} > PΣ,n
 ⋂
i:∆i>∆min
{
θˆi < θˆN − ci,ασiN
} . (3.5)
This inequality follows from noting that for all i,
{
θˆi < θˆN − ci,ασiN
}
⊂
{
θˆi < max
j 6=i
[θˆj − ci,ασij
}
. (3.6)
Theoretically, the bound obtained using (3.5) may be conservative, but it is often beneficial to be conservative
when conducting sample size calculations because of unpredictable circumstances such as loss to follow up,
patient dropout, and/or highly skewed responses. Since the normal distribution is a location-scale family, the
power only depends on the vector of effect sizes ∆ and not on θ. Henceforth, we will call the RHS of (3.5)
6 Author and Others
the power function and write Powerα,n (Σ,∆,∆min). It follows that
Powerα,n (Σ,∆,∆min) = PΣ,n
 ⋂
i:∆i>∆min
{
θˆi < θˆN − ci,ασiN
}
= PΣ,n
 ⋂
i:∆i>∆min
{√
n(θˆi − (θˆN −∆i))
σiN
√
n
< −ci,α + ∆i
√
n
σiN
√
n
}
= PΣ,n
 ⋂
i:∆i>∆min
{
Wi < −ci,α + ∆i
√
n
σiN
√
n
} , (3.7)
where W = (W1, ...,WM )
t ∼ N
(
0, Σ˜
)
and Σ˜ij = Cov
(√
n(θˆi − (θˆN −∆i))
σiN
√
n
,
√
n(θˆj − (θˆN −∆j))
σjN
√
n
)
,
and M is the number of indices i : ∆i > ∆min. Note that W , ci,α, and σiN
√
n =
√
Σii + ΣNN − 2ΣiN do
not depend on n since Σ does not depend on n. If the standardized effect sizes δi are specified instead of ∆i,
∆i may be computed as δiσiN
√
n.
It follows that the power may be computed by simulating normal random variables and substituting the
probability in (3.7) with the empirical mean Pn of the indicator variable.
Recall the main point of this paper is to assist investigators in choosing a sufficient number of individuals
to enroll in a SMART. To this end, we will derive a method for inverting Powerα,n (Σ,∆,∆min) with respect
to n. In particular, we are interested in finding the minimum n such that Powerα,n (Σ,∆,∆min) > 1−β. We
proceed by rewriting the power function expression:
Powerα,n (Σ,∆,∆min) = PΣ,n
 ⋂
i:∆i>∆min
{
θˆi < θˆN − ci,ασiN
}
= PΣ,n
 ⋂
i:∆i>∆min
{√
n(θˆi − θˆN + ∆i + ci,ασiN )
∆i
<
√
n
}
= PΣ,n
 ⋂
i:∆i>∆min
{
Xi <
√
n
}
= PΣ,n
 ⋂
i:∆i>∆min
{
Xi < c
∗
1−β
} , (3.8)
where X = (X1, ..., XM )
t ∼ N


c1,ασ1N
√
n/∆1
c2,ασ2N
√
n/∆2
...
cM,ασMN
√
n/∆M
 , Σ˜
, Σ˜ij = Cov
√n
(
θˆi − θˆN
)
∆i
,
√
n
(
θˆj − θˆN
)
∆j
,
M is the number of indices i : ∆i > ∆min, and c∗1−β is the 1−β equicoordinate quantile for the probability in
(3.8). It follows from (3.8) that n = (c∗1−β)
2. Here, we write the quantile c∗1−β with an asterisk to distinguish
it from the quantile ci,α which controls the type I error rate. If the standardized effect sizes δi are specified
instead of ∆i, ∆i may be computed as δiσiN
√
n. The constant c∗1−β may be computed using Monte Carlo
simulation to find the inverse of equation (3.8) after first computing the ci,α’s. The above procedure works
because the ci,α’s do not change with n, so the distribution of X is constant as a function of n. Our approach
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Algorithm 1 SMART Power Computation
1: Given Σ = Var(
√
nθˆ), compute ci,α for i = 1, .., N .
2: Given ∆ and ∆min, generate W
(k) =
(
W
(k)
1 , ...,W
(k)
M
)t
∼ N
(
0, Σ˜
)
, for k = 1, ...,m,
where Σ˜ij = Cov
(√
n(θˆi − (θˆN −∆i))
σiN
√
n
,
√
n(θˆj − (θˆN −∆j))
σjN
√
n
)
, m is the number of Monte Carlo repeti-
tions, and M is the number of indices i : ∆i > ∆min.
3: Compute the Monte Carlo probability
PowerMC,n,α (Σ,∆,∆min) ≈ Pm
1
 ⋂
i:∆i>∆
{
Wi < −ci,α + ∆i
√
n
σiN
√
n
} for some m ∈ N
where Pm denotes the empirical average.
for computing n is an extension of the sample size computation method in the appendix of Hsu (1996) to the
SMART setting when Σ is known. Algorithm 1 and Algorithm 2 use Monte Carlo simulation to calculate the
power and sample size, respectively, as a function of the covariance matrix and effect sizes.
Algorithm 1 and Algorithm 2 will be implemented in an R package ”smartsizer” freely available to
download for assisting investigators in planning SMARTs.
In the next section we will explore properties of the power function. We will see that the power is highly
sensitive to the choice of the covariance matrix Σ. This underscores the importance of using prior informa-
tion when conducting power calculations in order to obtain valid sample size and power predictions. Such
information may be obtained from pilot SMARTs and physicians’ knowledge of the variability in treatment
response.
4. Power Function Properties
Having derived an expression for the power function and provided an algorithm for its computation, we wish
to explore some of its properties. In particular, it is important to examine how sensitive the power is to the
choice of Σ when Σ is known. We will address the case in which Σ is unknown in Section 5. For simplicity,
we consider the most conservative case in which the effect sizes are all equal: ∆i = ∆ for all i.
In Figures 2-4, we evaluated the power function over a grid of values for Σ using Equation 3.6 and
Algorithm 1. These plots suggest the trend that higher correlations and lower variances tend to yield higher
power for both the exchangeable and non-exchangeable Σ. The correlation between best and non-best DTRs
appears to have a greater influence on power than the correlation between two inferior DTRs as we see in
Figure 2.
It is analytically difficult to prove monotonicity for a general Σ structure. However, as Figure 4 suggests,
it can be proven the power function is a monotone non-decreasing function of the correlation and a monotone
non-increasing function of the variance for an exchangeable covariance matrix. We conjecture this property
is true in general for n sufficiently large. We state the result below.
Theorem 4.1 Let Σ be exchangeable: Σ = σ2IN + ρσ
2 (1N1
′
N − IN ) where IN = diag(1, ..., 1) and 1N =
(1, ..., 1)′. Then, the power is a monotone increasing function of ρ and a monotone decreasing function of σ2.
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Algorithm 2 SMART Sample Size Estimation
1: Given Σ = Var(
√
nθˆ), compute ci,α for i = 1, .., N .
2: Given ∆ and ∆min, generate X
(k) =
(
X
(k)
1 , ..., X
(k)
M
)t
∼ N


c1,ασ1N
√
n/∆1
c2,ασ2N
√
n/∆2
...
cM,ασMN
√
n/∆M
 , Σ˜
 ,
for k = 1, ...,m, where Σ˜ij = Cov
√n
(
θˆi − θˆN
)
∆i
,
√
n
(
θˆj − θˆN
)
∆j
, m is the number of Monte Carlo
repetitions, and M is the number of indices i : ∆i > ∆min.
3: Find the empirical 1− β equicoordinate quantile c∗1−β of the simulated X(k) for each k = 1, ...,m.
4: Then, the sample size is n ≈
(
c∗1−β
)2
In order to simplify computations, we propose choosing a covariance matrix with fewer parameters than
the posited covariance matrix. That is, suppose E denotes the space of covariance matrices with fewer
parameters, and that the posited covariance matrix for the SMART is ΣTrue. For example, E may be the
space of exchangeable covariance matrices. We suggest choosing ΣExchangeable = arg min
Σ∈E
‖ΣTrue −Σ‖. For
example, ‖·‖ may be the Frobenius norm. In our simulation study, we will evaluate the power when choosing
the nearest exchangeable matrix in the Frobenius norm.
We also investigated the power as a function of the effect size assuming all effect sizes are equal by
computing over a grid of ∆ values. Figure 5 shows how the power is a monotone increasing function of the
uniform effect size ∆ which makes intuitive sense.
5. Simulation Study
We have explored how the power changes in terms of a known covariance matrix and effect size. In this
section, we present simulation studies for two different SMART designs in which we evaluate the assumption
of a known covariance matrix. In practice, the true covariance matrix is estimated consistently by some Σˆ.
The designs are based on those discussed in Ertefaie and others (2015). For each SMART, we simulate 1000
datasets across a grid of sample sizes n. We computed the sets of best EDTRs using the estimates θˆ and
Σˆ obtained from the AIPW estimation method after correctly specifying an appropriate marginal structural
model and conditional means (see Section 1.2, Proposition 1 of Appendix A in the supplementary material,
and Ertefaie and others (2015) for more details). For each n, the empirical power was calculated as the
fraction of data sets which excluded all EDTRs with true mean outcome ∆min or more away from the best
EDTR.
5.1 SMART Design: Example 1
In design 1, the stage-2 randomization is tailored based on response to the stage-1 treatment assignment. The
tailoring variable is the indicator V ∈ {R,NR} where a response corresponds to the intermediate outcome
O2 being positive. Non-responders to the first stage treatment are subsequently re-randomized to one of
two intervention options while responders continue on the initial treatment assignment. See Figure 9 in
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Appendix B of the supplementary material for more details. We generated 1000 data sets for each sample
size n = 50, 100, 150, 200, 250, 300, 350, 400, 450, 500 according to the following scheme:
1. (a) Generate O11, O12 ∼ N(0, 1) (baseline covariates)
(b) Generate A1 ∈ {−1,+1} from a Bernoulli distribution with probability 0.5 (first-stage treatment
option indicator)
2. (a) Generate O21 | O11 ∼ N(0.5O11, 1) and O22 | O12 ∼ N(0.5O12, 1) (intermediate outcomes)
(b) Generate ANR2 ∈ {−1,+1} from a Bernoulli distribution with probability 0.5 (second-stage treat-
ment option indicator for non-responders)
3. Y | O11, O12, O21, O22, A1, ANR2 ∼ N
(
1 +O11 −O12 +O22 +O21 +A1(δ + O112 ) + I(O21 > 0)ANR2
δ
2
, 1
)
where δ = 0.25
The parameter estimates βˆAIPW were computed using augmented-inverse probability weighting (AIPW) (see
Appendices A and B in the supplementary material and Ertefaie and others, 2015 for more details).
Then, θˆAIPW = DβˆAIPW where
D =

1 1 1
1 −1 1
1 1 −1
1 −1 −1
 . (5.9)
The rows of D correspond to each of the four EDTRs as listed in the supplementary material.
The true θ was (1.312, 0.812, 1.188, 0.688). The minimum effect size ∆min was set to 0.5 and the vector of
effect sizes was set to (0, 0.5, 0.124, 0.624) for estimating the anticipated power. We computed the set of best
DTRs using the multiple comparison with the best procedure as outlined in Section 2.4 for each data set and
sample size. The empirical power was calculated as the fraction of data sets which excluded all EDTRs with
true mean outcome ∆min or more away from the best EDTR (in this case EDTR2 and EDTR4), for each
n. The true covariance matrix for this SMART was estimated by averaging 1000 simulated datasets each of
10000 individuals. ΣExchangeable is the closest matrix in Frobenius norm to ΣTrue of the form
σ2 ρσ2 ρσ2 ρσ2
ρσ2 σ2 ρσ2 ρσ2
ρσ2 ρσ2 σ2 ρσ2
ρσ2 ρσ2 ρσ2 σ2

5.1.1 Example 1: results The simulation results are summarized in the plot on the left-hand side of Figure
6. The plot shows the sample size calculation is highly sensitive to the choice of Σ. Choosing Σ = I4 will
greatly underestimate the required sample size, predicting around 100 individuals compared to the true 400-
450 individuals needed to achieve 80% power. This implies it is important not to ignore the variance of DTRs.
Consequently, it is very important to utilize prior information such as that obtained from pilot SMARTs and
physician’s knowledge of treatment response variability in order to make an informed choice for the covariance
matrix and to obtain accurate sample size predictions.
5.2 SMART Design: Example 2
In the second SMART design, stage-2 randomization depends on both prior treatment and intermediate
outcomes (Ertefaie and others, 2015). In particular, Individuals are randomized at stage-2 if and only
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if they are non-responders whose stage-1 treatment option corresponded to A1 = −1 (call this condi-
tion B) (see Appendix B Figure 10 for more details). We generated 1000 data sets for each sample size
100, 150, 200, 250, 300, 350, 400, 450, 500 according to the following scheme:
1. (a) Generate O11, O12 ∼ N(0, 1) (baseline covariates)
(b) Generate A1 ∈ {−1,+1} from a Bernoulli distribution with probability 0.5 (first-stage treatment
option indicator)
2. (a) Generate O21 | O11 ∼ N(0.5O11, 1) and O22 | O12 ∼ N(0.5O12, 1) (intermediate outcomes)
(b) Generate AB2 ∈ {1, 2, 3, 4} from a Multinomial distribution with probability 0.25 (second-stage
treatment option indicator for individuals satisfying condition B)
3. Y | O11, O12, O21, O22, A1, AB2 ∼ Normal with unit variance and mean equal to
1 +O11 −O12 +O21 +O22 + I(A1 = −1)(δ +O11)
+ I(O21 > 0)I(A1 = −1)[−δ/4I(A2 = 1) + δ/2I(A2 = 2) + 0I(A2 = 3) + δ/2O21I(A2 = 2)]
where δ = 2.00
The parameter estimates βˆAIPW were computed using AIPW (see Appendices A and B in the supplementary
material and Ertefaie and others, 2015 for more details). Then, θˆAIPW = DβˆAIPW where
D =

1 0 0 0 0
1 1 0 0 0
1 1 1 0 0
1 1 0 1 0
1 1 0 0 1
 . (5.10)
The true β value is (1.00, δ,−δ/8, δ/4, 0) where δ = 2.00 and the true θ value is (1.00, 3.00, 2.75, 3.50, 3.00).
Note the fourth EDTR is the best.
We let the vector of effect sizes ∆ = (2.50, 0.50, 0.75, 0.00, 0.50) and the desired detectable effect size
∆min = 0.5. The set of best was computed for each data set. For each sample size, the empirical power is the
fraction of 1000 data sets which exclude EDTR1,EDTR2,EDTR3,EDTR5.
5.2.1 Example 2: Results Our simulation results are summarized in the plot on the right-hand size of Figure
6. The true covariance matrix for this SMART was computed by averaging 1000 simulated datasets each of
10000 individuals. The power plots show that the predicted power is similar to the empirical power when
assuming both the correct ΣTrue and for Σ of the form
σ21 ρ1σ1σ2 ρ1σ1σ2 ρ1σ1σ2 ρ1σ1σ2
ρ1σ1σ2 σ
2
2 ρ2σ
2
2 ρ2σ
2
2 ρ2σ
2
2
ρ1σ1σ2 ρ2σ
2
2 σ
2
2 ρ2σ
2
2 ρ2σ
2
2
ρ1σ1σ2 ρ2σ
2
2 ρ2σ
2
2 σ
2
2 ρ2σ
2
2
ρ1σ1σ2 ρ2σ
2
2 ρ2σ
2
2 ρ2σ
2
2 σ
2
2

with parameters ρ1, ρ2, σ
2
1 , σ
2
2 chosen to minimize the Frobenius distance to ΣTrue (see Appendix B of the
supplementary materials for more details). The anticipated sample size is approximately 500 individuals for
ΣTrue.
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6. Illustration: EXTEND Retrospective Power Computation
In this section, we will apply our power analysis method to examine how much power there was to distinguish
between DTRs ∆min away from the best in the EXTEND SMART when using MCB. Please see Section 2.1
for more details about the EXTEND SMART and Figure 1 for a diagram depicting the EXTEND SMART.
The outcome of interest was the Penn Alcohol Craving Scale (PACS) and the lower PACS were considered
better outcomes. The covariance matrix Σˆ and the vector of EDTR outcomes θ were estimated using both
IPW and AIPW (see Appendix A and Proposition 1 of the supplementary material for more details about
estimation procedures). The covariance matrices are given below:
ΣˆIPW = Var(
√
nθˆIPW) =

145.86 54.88 77.24 −13.74 101.55 10.57 32.93 −58.05
54.88 163.02 1.13 109.27 12.66 120.8 −41.09 67.05
77.24 1.13 125.54 49.42 33.34 −42.77 81.64 5.53
−13.74 109.27 49.42 172.43 −55.55 67.46 7.62 130.63
101.55 12.66 33.34 −55.55 138.36 49.47 70.16 −18.73
10.57 120.8 −42.77 67.46 49.47 159.71 −3.87 106.37
32.93 −41.09 81.64 7.62 70.16 −3.87 118.86 44.84
−58.05 67.05 5.53 130.63 −18.73 106.37 44.84 169.94

ΣˆAIPW = Var(
√
nθˆAIPW) =

113.35 32.52 82.01 1.19 103.8 22.97 72.46 −8.36
32.52 143.74 −13.93 97.28 25.91 137.12 −20.55 90.67
82.01 −13.93 123.63 27.69 72.32 −23.63 113.94 17.99
1.19 97.28 27.69 123.78 −5.58 90.52 20.92 117.02
103.8 25.91 72.32 −5.58 112.1 34.21 80.62 2.73
22.97 137.12 −23.63 90.52 34.21 148.36 −12.39 101.76
72.46 −20.55 113.94 20.92 80.62 −12.39 122.09 29.08
−8.36 90.67 17.99 117.02 2.73 101.76 29.08 128.11

The EDTR outcome vectors θˆIPW and θˆAIPW are summarized in Table 1.
The set of best when performing estimation using AIPW excluded EDTR6 and EDTR8, both of which
had effect size greater than 2 away from the best EDTR, EDTR1. The set of best when using IPW failed
to exclude any of the inferior EDTR (Ertefaie and others, 2015). In order to evaluate the power there was
to exclude EDTR6 and EDTR8 in EXTEND when using AIPW, we set the minimum detectable effect size
∆min to 2.
At an α level of 0.05, the power to exclude all DTRs inferior to the best one by 2 or more was 27%
for IPW and 46% for AIPW. AIPW yields greater power than IPW because AIPW yields smaller standard
errors compared with IPW (Ertefaie and others, 2015). Our method estimates that a total of 717 individuals
would need to be enrolled to achieve a power of 80% using IPW and a total of 482 individuals would need to
be enrolled when using AIPW.
In Figure 7, we computed the power over a grid of ∆ values to see how the power changes as a function
of effect size.
In Figure 8, we show how the power changes as a function of a uniform effect size. Specifically, we assume
EDTR1 is the best and set the effect sizes of EDTR2, ...,EDTR8 to be equal. We then vary this uniform
effect size. In this case, we ignore the actual effect sizes of the true EDTR estimates θˆ. In both Figures 7 and
8, we see the trend that AIPW yields greater power when compared with IPW.
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7. Discussion
One of the main goals of SMART designs is determination of an optimal dynamic treatment regimen. When
planning SMART designs, it is hence crucial to enroll a sufficient number of individuals in order to be able
to detect the best DTR and to be able to exclude DTRs inferior to the best one by a clinically significant
quantity.
In this paper, we introduced a novel method for carrying out power analyses for SMART designs which
leverages multiple comparison with the best and Monte Carlo simulation. Our methodology directly addresses
the central goal of SMARTs.
We explored the sensitivity of our method to varying parameters in the covariance matrix. We saw that
the power prediction is greatly affected by the particular choice of the covariance matrix. This underscores
the importance of relying on previous data such as a pilot SMART to estimate Σ. We saw in simulation
studies that our method yields valid estimates of power and it appears similar results may be achieved by
choosing exchangeable “close” covariance matrices to the true covariance matrix.
We illustrated our method on the EXTEND SMART to see how much power there was to exclude inferior
DTRs from the set of best and the necessary sample size to achieve 80% power.
Future work will involve developing ways of choosing Σ using pilot SMART data and for sizing pilot
SMARTs with the ability to estimate the covariance matrix to a specified accuracy.
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Fig. 1. This diagram show the structure of the EXTEND trial.
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Σ =
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2
 and i = 4 is the best DTR. ∆ = (0.25, 0.25, 0.25, 0) and ∆min = 0.25
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Fig. 5. The plot of power against the uniform effect size for Σ = I4,ΣTRUE shows that as the effect size ∆ → ∞,
Power(∆) → 1 and similarly Power(∆) → 0 as ∆ → 0. ΣTRUE is the true covariance matrix form simulation design
1. Furthermore, the plot demonstrates the power is a monotone increasing function of the effect size ∆. A proof can
be derived using continuity and monotonicity of the probability measure.
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The plot shows the power curves for Σ = I4,Σ = ΣTrue, and Σ = ΣExchangeable and the empirical power curve.
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Fig. 7. This plot shows the power as a function of ∆min in the EXTEND trial when performing estimation with IPW
and AIPW, respectively. There are 250 individuals in EXTEND
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.0 0.5 1.0 1.5 2.0 2.5
Effect Size ∆
Po
w
e
r Method
IPW
AIPW
Power vs. Equal Effect Size
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estimation with IPW and AIPW, respectively. There are 250 individuals in EXTEND
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Table 1. Extend trial: parameter estimates and standard errors
Parameter θ1 θ2 θ3 θ4 θ5 θ6 θ7 θ8
IPW Estimate 7.56 9.53 8.05 10.02 7.71 9.68 8.19 10.17
SD 0.76 0.81 0.71 0.83 0.74 0.80 0.69 0.82
AIPW Estimate 7.65 9.44 7.83 9.62 8.06 9.85 8.24 10.03
SD 0.67 0.76 0.70 0.70 0.67 0.77 0.70 0.72
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Supplementary Material
Appendix A.
9. Notation
We focus on notation for two-stage SMART designs, but the methods in this paper are applicable to an
arbitrary SMART. Let EDTRi denote the ith EDTR. Let Oj and Aj denote the observed covariates and
treatment assignment, respectively, at stage j. Let O¯j and A¯j denote the covariate and treatment histories
up to and including stage j, respectively. Let T the treatment trajectory be the vector of counterfactual
treatment assignments for an individual. For example, in a two-stage SMART with response as a tailoring
variable, T may be of the form T = (A1, AR2 , ANR2 ) where AR2 is the stage two treatment assignment had
the individual responded and ANR2 is the stage two treatment assignment had the individual not responded.
The reason these are counterfactual treatment assignments is that for an individual who responds to the
stage 1 treatment, ANR2 would be unobserved. Hence, the treatment history A¯2 would be (A1, A2) while the
treatment trajectory T would be (A1, AR2 , ANR2 ) and would include the unobserved counterfactual. Let Y
denote the observed outcome of an individual at the end of the study. A tailoring variable may be written
as V and is a function of the observed covariates and treatment assignments at each stage. Let S be an
indicator for randomization at stage 2. Then, the data structure for a two-stage SMART may be written
(O1, A1, O2, S,A2, Y ) (Ertefaie and others, 2015).
10. Estimation
We summarize the estimation procedures IPW (inverse probability weighting) and AIPW (augmented in-
verse probability weighting) introduced in Ertefaie and others (2015). In order to perform estimation with
IPW/AIPW, a marginal structural model (MSM) must be specified. An MSM models the response as a
function of the counterfactual random treatment assignments captured in the treatment trajectory vector T ,
while ignoring non treatment covariates. For example, in a two-stage SMART, the MSM is:
m(T ;β) = β0 + β1A1 + β2AR2 + β3ANR2 + β4A1AR2 + β5A1ANR2 .
Subsequently, the IPW and AIPW estimators θˆIPW, θˆAIPW may be obtained by solving their respective
estimating equations:
Pn
K∑
k=1
m˙(T ;β)w2(V, A¯2, k)(Y −m(T ;β) = 0 (IPW)
Pn
K∑
k=1
m˙(T ;β)[w2(V,A2, k)(y −m(T ,β))
− (w2(V, A¯2, k)− w1(A1, k)) (E[Y | A¯2 = EDTRVk , O¯2]−m(T ;β))
− (w1(A1, k)− 1)(E[E[Y | A¯2 = EDTRVk , O¯2] | A1 = EDTRk,1, O1]−m(T ;β)
)
= 0
(AIPW)
where Pn denotes the empirical average, m˙(T ,β) = ∂m
∂β
, EDTRVk =
(
EDTRk,1,EDTR
V
k,2
)
, w1(a1, k) =
IEDTRk,1(a1)
p(A1 = a1)
for A1 = a1, and w2(v, a¯2, k) =
IEDTRk,1(a1)IEDTRvk,2(a2)
p(A1 = a1)p(A2 = a2 | A1 = a1, V = v) for V = v and A¯2 = a¯2.
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AIPW is doubly-robust in the sense that it will still provide unbiased estimates of the MSM coefficients
β when either the conditional means or the treatment assignment probabilities are correctly specified.
The following proposition from Ertefaie and others (2015) is included for the sake of completeness.
Proposition 1. Let θˆ = Dβˆ, where D is a K × p matrix with the kth row of D being the contrast
corresponding to the kth EDTR. Then, under standard regulatory assumptions,
√
n(θˆ − θ) → N(0,Σ =
D[Γ−1ΛΓ′−1]D′) where Γ = −E[∑Ki=1 m˙(T ;β)m˙′(T ;β)] and Λ = E[UU ′] with
UAIPW =
K∑
k=1
m˙(T ;β)[w2(V,A2, k)(y −m(T ,β))− (w2(V, A¯2, k)− w1(A1, k)) (E[Y | A¯2 = EDTRVk , O¯2]−m(T ;β))
− (w1(A1, k)− 1)(E[E[Y | A¯2 = EDTRVk , O¯2] | A1 = EDTRk,1, O1]−m(T ;β)
)
U IPW =
K∑
k=1
m˙(T ;β)w2(V, A¯2, k)(Y −m(T ;β).
The asymptotic variance Σ may be estimated consistently by replacing the expectations with expectations
with respect to the empirical measure and (β, γ) with its estimate (βˆ, γˆ) and may be denoted as Σˆ

=
D[Γˆ−1ΛˆΓˆ′−1]D′
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11. Proof of Theorem 4.1
Note that Cov
(√
n(θˆi − θˆN )
σiN
,
√
n(θˆj − θˆN
σjN
)
=
Σij − ΣiN − ΣjN + ΣNN
σiNσjN
.
Assume Σ is exchangeable, e.g., Σ = σ2IN + ρσ
2 (1N1
′
N − IN ) where 1N is a vector of N 1′s and IN is
the N by N identity matrix.
Then, for all i, j, Cov (Wi,Wj) = Cov
(√
n(θˆi − θˆN )
σiN
,
√
n(θˆj − θˆN
σjN
)
=
ρσ2 − 2ρσ2 + σ2
2σ2(1− ρ) =
σ2(1− ρ)
2σ2(1− ρ) =
1
2
for all ρ ∈
(
− 1
N − 1 , 1
)
and for all σ2. Also, ci,α is constant across all values of ρ and σ
2.
It follows from Slepian’s inequality and monotonicity of the probability measure that
Powerα,n (Σ,∆,∆min) = PΣ
(
N−1⋂
i=1
{
Wi < −ci,α + ∆i
√
n√
2σ2(1− ρ)
})
is monotone increasing in ρ and monotone decreasing in σ2.
12. Simulation Study
In this section of the supplementary material, we give additional details on how estimation was performed
in the simulation study. The SMART designs in the simulation studies are based off the SMART designs of
the simulation studies of Ertefaie and others (2015). We estimated θ and Σ using AIPW
For SMART design 1, the MSM is m(T ;β) = β0 + β1A1 + β2ANR2 . The true conditional means are:
E[Y | A¯2 = EDTRVk , O¯2] = γ0 + γ1o11 + γ2o12 + γ3o21 + γ4o22 + a1(γ5 + γ6o11) + γ7I(O21 > 0))a2
E[Y | A1 = EDTRk,1, O1] = γ8 + γ9o11 + γ10o12 + γ11a1 + γ12a1o11
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Fig. 9. SMART Design 1
For SMART design 2, the MSM is:
m(T ;β) = β0 + β1I(A1 = −1) + I(A1 = −1)[β2I(AB2 = 1) + β3I(AB2 = 2) + β4I(AB2 = 3)].
The true conditional means are:
E[Y | a¯2 = EDTRVk , o¯2,γ] =γ0 + γ1o11 + γ2o12 + γ3o21 + γ4o22 + I(a1 = −1)(γ5 + γ6o11)
+ I(o21 > 0)I(a1 = −1)[γ7I(a2 = 1) + γ8I(a2 = 2) + γ9I(a2 = 3) + γ10o21I(a2 = 2)]
E[Y | a1 ∈ EDTRk,1, o1,γ] =γ11 + γ12o11 + γ13o12 + γ14I(a1 = −1) + γ15I(a1 = −1)o11
12.1 Simulation SMART design 1: Determination of the Closest Exchangeable Matrix
Let Σ be exchangeable and ‖·‖ denote the Frobenius norm. Then, Σ is of the form Σ = σ2IN+ρσ2 (1N1′N − IN ).
Hence,
‖Σ−ΣTrue‖2 =
∥∥σ2IN + ρσ2 (1N1′N − IN )−ΣTrue∥∥2 := N∑
i=1
(σ2 − σ2i )2 +
∑∑
i 6=j
(ρσ2 − σij)2
Then,
∂
∂σ2
‖Σ−ΣTrue‖2 = 2
N∑
i=1
(σ2 − σ2i ) + 2ρ
∑∑
i 6=j
(ρσ2 − σij) = 0
and
∂
∂ρ
‖Σ−ΣTrue‖2 = 2σ2
∑∑
i 6=j
(ρσ2 − σij) = 0.
Hence,
σ2 =
1
N
N∑
i=1
σ2i and ρσ
2 =
1
N(N − 1)
∑∑
i 6=j
σij
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12.2 Simulation 2: Determination of the closest exchangeable matrix
We assumed a block exchangeable matrix for Σ of the form
ΣExchangeable =

σ21w ρ1σ1wσ2w ρ1σ1wσ2w ρ1σ12σ2w ρ1σ1wσ2w
ρ1σ1wσ2w σ
2
2w ρ2σ
2
2w ρ2σ
2
2w ρ2σ
2
2w
ρ1σ1wσ2w ρ2σ
2
2w σ
2
2w ρ2σ
2
2w ρ2σ
2
2w
ρ1σ1wσ2w ρ2σ
2
2w ρ2σ
2
2w σ
2
2w ρ2σ
2
2w
ρ1σ1wσ2w ρ2σ
2
2w ρ2σ
2
2w ρ2σ
2
2w σ
2
2w

Note that
‖ΣExchangeable −ΣTrue‖ = (σ1w−σ21)2 +
5∑
i=2
(σ22w−σ22)2 + 2
5∑
j=2
(ρ1σ1wσ2w−σ1j)2 +
∑∑
i 6=j∈{2,3,4,5}
(ρ2σ
2
2w−σij).
Hence,
∂
∂σ21w
‖Σ−Σclose‖ = 2(σ21w − σ21) + 4ρ1σ2w
5∑
j=2
(ρ1σ1wσ2w − σ1j) = 0
∂
∂ρ1
‖Σ−Σclose‖ = 4σ1wσ2w
5∑
j=2
(ρ1σ1wσ2w − σ1j) = 0
∂
∂σ22w
‖Σ−Σclose‖ = 2
5∑
i=2
(σ22w − σ2i ) + 4ρ1σ1w
5∑
j=2
(ρ1σ1wσ2w − σ1j) + 2ρ2
∑∑
i6=j,1
(ρ2σ
2
2w − σij)
∂
∂ρ2
‖Σ−Σclose‖ = 2σ22w
∑∑
i 6=j,1
(ρ2σ
2
2w − σij)
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Hence,
σ21w = σ1w
σ22w =
1
4
5∑
j=2
σ2j
ρ1σ1wσ2w =
1
4
5∑
j=2
σ1j
ρ2σ
2
2w =
1
12
∑∑
j 6=i∈{2,3,4,5}
σij
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